NICE accepts PAD treatment

Intermittent claudication can significantly impair mobility in people with PAD. | SCIENCE PHOTO LIBRARY
Intermittent claudication can significantly impair mobility in people with PAD. | SCIENCE PHOTO LIBRARY

Naftidrofuryl oxalate can now be prescribed on the NHS for the treatment of intermittent claudication caused by peripheral arterial disease (PAD). It may be used in patients for whom vasodilator therapy is considered appropriate.

Although naftidrofuryl oxalate does not halt the progression of PAD, it is believed to be the most clinically and cost effective treatment option in terms of improving maximum walking distance.

NICE rejected the other vasodilators cilostazol, pentoxifylline and inositol nicotinate for intermittent claudication in PAD on the grounds that they are not as clinically effective compared with placebo as naftidrofuryl oxalate.

View naftidrofuryl drug record

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Antidiabetic Agents, Use in Renal Impairment

Antidiabetic Agents, Use in Renal Impairment

Dosing of diabetes drugs in patients with renal impairment.

Insulin Delivery Devices

Insulin Delivery Devices

Features and compatibility of insulin pens.

Drug shortages - live tracker

Drug shortages - live tracker

Check on the latest drug supply issues with MIMS' shortages...

Blood Glucose Testing Strips and Meters

Blood Glucose Testing Strips and Meters

Compatible test strips for blood glucose meters.